VYEPTI is indicated for the preventive treatment of migraine in adults.
VYEPTI is indicated for the preventive treatment of migraine in adults.

Flexible options for referring patients to infusion locations

Including:

  • The VYEPTI Infusion Network
  • Stand-alone infusion location or part of local hospital or healthcare system organization
  • Home infusion
  • Provider's office

VYEPTI Infusion Network

Lundbeck partners with a network of infusion providers to deliver a consistent VYEPTI treatment experience in a convenient location for your patients.

With the VYEPTI Infusion Network, your patients can expect*:

""

Touchpoints to keep the prescriber informed
pre- and post-treatment, including next infusion date

""

Help enrolling in the VYEPTI CONNECT Copay Assistance Program†

""

Assistance with benefits investigations and prior
authorizations

Patients can also expect a welcome phone call from the infusion provider, which may come from an unrecognized number. Please remind patients to be aware of this upcoming call.*

Referral forms for our provider partners

VYEPTI administration is not limited to the VYEPTI Infusion Network; Lundbeck does not recommend the use of any specific infusion site.

Infusion for Health, IVX Health, and Vivo Infusion only consist of outpatient infusion sites. Home infusion may be an option, depending on your patient's insurance coverage. Some insurers may require VYEPTI to be infused in certain sites of care by specific in-network infusion providers. For general questions about the VYEPTI Infusion Network, contact your Sales Representative.  

*Other infusion providers may also have these offerings.

†For eligible patients with commercial insurance.

Help avoid delays when referring out

Follow these 3 steps:

  • Ensure the referral form is completed with all the required information
  • Include a copy of the patient’s medical and insurance cards (front and back)
  • Attach chart notes including migraine and medication history that satisfy the patient’s insurance requirements (details to include: number of headache and migraine days per month; all treatments tried, failed, or discontinued, along with reasons)

NOTE: Remind patients that they may receive a welcome phone call from the infusion provider, which may come from a number they do not recognize. It is important to answer the call or promptly call them back.

Additional infusion site options

While these locations are outside the optional VYEPTI Infusion Network, they may be in network with your patient's insurance provider. Use the VYEPTI Infusion Locator to find a location near your patients. When selecting the best infusion location for a patient, it is important to consider affordability alongside convenience, as some healthcare plans have different coverage and costs based on site of care.

""
Infusion locations
  • A stand-alone infusion location or part of a local hospital or healthcare system organization
""
Home infusion
""
Provider's office
Map with location pins.

Use the VYEPTI Infusion Locator

Find a VYEPTI Infusion Network location, or other infusion site, near your patients.

VYEPTI administration is not limited to the VYEPTI Infusion Network; Lundbeck does not recommend use of any specific infusion provider. 

DISCOVER INFUSION LOCATIONS

Ordering VYEPTI

VYEPTI national drug code

100 mg/mL Solution in Single-Dose Vial
10-digit format
67386-130-51		 11-digit format for claims submissions
67386-0130-51

""

The specialty distributor will ship VYEPTI to your site, typically within 1 business day.
For more information on the process, download the VYEPTI Access Guide.

Specialty pharmacies included in VYEPTI’s network 

Select the pharmacy name to download their prescription form. 

Option Care Health logo.

Option Care Health

P: 844-789-3784

Lundbeck does not recommend the use of any particular specialty pharmacy or specialty distributor.

Communicate with the specialty pharmacy

  • It’s important for you or the infusion site to communicate with the specialty pharmacy in case more information is needed to verify your patients’ coverage and to coordinate shipments

Prepare your patients

  • Your patients will be contacted directly for permission to ship VYEPTI
    – Remind your patients it’s important to answer calls from the specialty pharmacy or to promptly call them back
  • To avoid the call appearing as “unknown,” please have your patients add the specialty pharmacy number to their phone contacts

The specialty pharmacy will coordinate shipment details based on the infusion schedule with your infusion site.

Ordering requirements, which can be determined during the benefits verification process, may differ based on the patient’s healthcare plan coverage.

VYEPTI CONNECT® logo.

Starting VYEPTI

Helping connect patients to the treatment they have been prescribed

VYEPTI CONNECT® provides Patient Navigators, who can assist with coverage investigation, in-network infusion location identification, financial assistance options for eligible patients, and Nurse Educators for treatment questions.

LEARN MORE ABOUT VYEPTI CONNECT

Expert office managers and a migraine specialist discuss helping patients along their treatment journey

Expert office managers and a migraine specialist discuss helping patients along their treatment journey

Select any chapter within the video player to view that content.

Chapter 1: Introduction to VYEPTI®

A migraine specialist and expert office practice managers discuss VYEPTI®: Helping patients along their treatment journey

Chapter 2: In-Office IV Infusion

On-hand experiences to help VYEPTI® IV administration

Chapter 3: Referring Patients Out

On-hand experiences to help with VYEPTI® IV administration at an alternate site of care

Chapter 4: Panel Discussion

Integrating insights with VYEPTI® administration: Putting it all together

VYEPTI Access Guide.

VYEPTI Access Guide

A guide to support your office and your patients with coverage, reimbursement, and infusion information

DOWNLOAD NOW
""

Questions regarding infusion options or payer coverage for your patients? The VYEPTI field team is here to help. 

CONTACT A REP

""
IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI
in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and institute appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of monoclonal antibody CGRP antagonists, including VYEPTI, in the postmarketing setting. There were cases with monoclonal antibody CGRP antagonists that required hospitalization, including cases where surgery was necessary. In a majority of these cases, the onset of constipation was reported after the first dose; however, patients have also presented with constipation later on in treatment. The monoclonal antibody CGRP antagonist was discontinued in many of the reported cases of constipation with serious complications.

Monitor patients treated with VYEPTI for severe constipation and manage as clinically appropriate. The concurrent use of medications that reduce gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including VYEPTI, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension, and in some cases hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. The CGRP antagonist was discontinued in many of the reported cases.

Monitor patients treated with VYEPTI for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of VYEPTI is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists. In reported cases with monoclonal antibody CGRP antagonists, symptom onset occurred a median of 71 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.

VYEPTI should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.

IMPORTANT SAFETY INFORMATION AND INDICATION
CONTRAINDICATIONS

VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, dyspnea, and rash, have occurred with VYEPTI
in clinical trials and in the postmarketing setting. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have been reported in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI and institute appropriate therapy.

Constipation with Serious Complications: Constipation with serious complications has been reported following the use of monoclonal antibody CGRP antagonists, including VYEPTI, in the postmarketing setting. There were cases with monoclonal antibody CGRP antagonists that required hospitalization, including cases where surgery was necessary. In a majority of these cases, the onset of constipation was reported after the first dose; however, patients have also presented with constipation later on in treatment. The monoclonal antibody CGRP antagonist was discontinued in many of the reported cases of constipation with serious complications.

Monitor patients treated with VYEPTI for severe constipation and manage as clinically appropriate. The concurrent use of medications that reduce gastrointestinal motility may increase the risk for more severe constipation and the potential for constipation-related complications.

Hypertension: Development of hypertension and worsening of pre-existing hypertension have been reported following the use of CGRP antagonists, including VYEPTI, in the postmarketing setting. Some of the patients who developed new-onset hypertension had risk factors for hypertension. There were cases requiring initiation of pharmacological treatment for hypertension, and in some cases hospitalization. Hypertension may occur at any time during treatment, but was most frequently reported within 7 days of therapy initiation. The CGRP antagonist was discontinued in many of the reported cases.

Monitor patients treated with VYEPTI for new-onset hypertension or worsening of pre-existing hypertension, and consider whether discontinuation of VYEPTI is warranted if evaluation fails to establish an alternative etiology or blood pressure is inadequately controlled.

Raynaud’s Phenomenon: Development of Raynaud’s phenomenon and recurrence or worsening of pre-existing Raynaud’s phenomenon have been reported in the postmarketing setting following the use of CGRP antagonists. In reported cases with monoclonal antibody CGRP antagonists, symptom onset occurred a median of 71 days following dosing. Many of the cases reported serious outcomes, including hospitalizations and disability, generally related to debilitating pain. In most reported cases, discontinuation of the CGRP antagonist resulted in resolution of symptoms.

VYEPTI should be discontinued if signs or symptoms of Raynaud’s phenomenon develop, and patients should be evaluated by a healthcare provider if symptoms do not resolve. Patients with a history of Raynaud’s phenomenon should be monitored for, and informed about the possibility of, worsening or recurrence of signs and symptoms.

ADVERSE REACTIONS

The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

INDICATION

VYEPTI is indicated for the preventive treatment of migraine in adults.

For more information, please see the Full Prescribing Information and Patient Information.